Targeting the Root Cause Through First Principles
We're pioneering a revolutionary approach to Alzheimer's disease by targeting what actually drives neurodegeneration. Instead of trying to eliminate tau—the strongest correlate of cognitive decline—we're detoxifying it, preserving its essential functions while blocking its pathological effects.
Discover Our Approach →After decades and billions invested, we still don't have effective Alzheimer's treatments. Here's why the field needs a fundamental rethink.
Current therapeutics chase symptoms, not causes. Amyloid-beta approaches have consistently failed because they don't address the actual driver of neurodegeneration—pathological tau.
Tau pathology tracks perfectly with cognitive decline and neuronal death. It's the strongest correlate of neurodegeneration, yet most approaches ignore it or try to eliminate it entirely—a fatal mistake.
Current tau-targeting approaches use antibodies or ASOs to deplete tau entirely. But tau is essential for neuronal function—removing it causes as much harm as the disease itself.
The devastating impact and repeated failures demand a new approach.
We've identified the fundamental problem: it's not tau itself, but specific toxic interactions tau forms during disease. Our breakthrough approach detoxifies tau by blocking only these pathological interactions while preserving essential functions.
This isn't incremental improvement—it's addressing the root cause for the first time. By mapping tau's interaction network and selectively disrupting only harmful connections, we can halt neurodegeneration without compromising neuronal health.
Multiple complementary approaches to maximize success probability, each targeting distinct aspects of tau toxicity.
Lead optimization stage targeting critical tau interaction pathway
Hit-to-lead stage with novel mechanism of tau detoxification
Discovery stage exploring additional tau modulation approach
Strategic use of capital to achieve critical milestones before Series A.
High-throughput screening campaign to identify initial hits from 500K+ compound libraries
DNA-Encoded Library screening to explore billions of compounds for novel chemical matter
Validate compounds demonstrate on-target activity and selective tau detoxification
Advance compounds to lead status with confirmed in vitro efficacy and drug-like properties
We're seeking visionary investors who understand that defeating Alzheimer's requires more than incremental improvements—it demands a fundamental rethinking of the problem. Request our scientific presentation to learn how we're finally addressing the root cause.